Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350877 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2735604 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2352413 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2351564 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11753530 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL27965 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11032494 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11518271 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL8846723 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL95500 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087246-A1 | BIOTECHNOLOGICAL PRODUCTION OF PHYTOL | BASF SE (DE) | 2026-04-30 | — | — | WO | claimed |
| WO-2012069149-A1 | SOLUTION COMPRISING CYCLIC OLIGOPEPTIDES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | claimed |
| US-7579374-B2 | Agent for improving bone metabolism | THE NISSHIN OILLIO GROUP, LTD. (JP) | 2009-08-25 | — | — | US | claimed |
| EP-2004159-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | Biovitrum AB (publ) (SE) | 2008-12-24 | — | — | EP | claimed |
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | BIOVITRUM AB (SE) | 2008-02-28 | — | — | US | claimed |
| WO-2007104790-A1 | AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS | BIOVITRUM AB (PUBL) (SE) | 2007-09-20 | — | — | WO | claimed |
| US-20040058995-A1 | Agent for improving bone metabolism | THE NISSHIN OILLIO, LTD. | 2004-03-25 | — | — | US | claimed |
| US-4293497-A | ALKYLATION CATALYSTS, VIATMIN E | SCM CORPORATION (US) | 1981-10-06 | — | — | US | claimed |
| JP-5097876-A | — | — | None | — | — | JP | disclosed |
| WO-2026087246-A1 | BIOTECHNOLOGICAL PRODUCTION OF PHYTOL | BASF SE (DE) | 2026-04-30 | — | — | WO | disclosed |
| US-20260085081-A1 | PHOSPHATIDYLAMINE COMPOUNDS INCLUDING A PLURALITY OF TERTIARY AMINO GROUP STRUCTURES AND COMPOSITIONS THEREOF | PEKING UNIVERSITY (CN) | 2026-03-26 | — | — | US | disclosed |
| EP-2788006-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4674856-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12516080-B2 | Remdesivir and remdesivir analogs, solutions, and nanoparticle, liposomal, and microparticle compositions for treating viral infections | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-01-06 | — | — | US | disclosed |
| US-4292454-A | INTERMEDIATES FOR VITAMIN E | SCM CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
| US-4228313-A | TO PREPARE A REARRANGED UNSATURATED HYDROCARBON | SCM CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
| US-4221742-A | Coupling reaction involving a Grignard and allylic halide | SCM CORPORATION (US) | 1980-09-09 | — | — | US | disclosed |
| US-4221810-A | TOCOPHERYL DERIVATIVES | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1980-09-09 | — | — | US | disclosed |
| US-4011334-A | USE OF SUBSTITUTED FURAN AND THIOPHENE CARBOXALDEHYDES AS HYPOLIPIDEMIC AGENTS | RICHARDSON-MERRELL INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-3972847-A | PEROXIDES | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051451-A1 | Autoimmune conditions and NADPH oxidase defects | CYBB, NOX1, NOX5 | LMNA 4180/4885BLM 2996/4885PTPN1 790/4885 |
| US-20040058995-A1 | Agent for improving bone metabolism | FABP2, FABP4, SREBF2 | LMNA 3220/4885BLM 4705/4885PTPN1 4636/4885 |
| US-20260085081-A1 | PHOSPHATIDYLAMINE COMPOUNDS INCLUDING A PLURALITY OF TERTIARY AMINO GROUP STRUCTURES AND COMPOSITIONS THEREOF | SGMS1, PHOSPHO1, SGMS2 | LMNA 339/4885BLM 2191/4885PTPN1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.